You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A Novel Therapeutic to Promote Corneal Repair
SBC: MICROCURES INC Topic: NEIThe cornea is one of the most important tissues in the eye and its transparency is critical for good visual function in humans. Corneal tissue injuries are the most common, everyday issue for practicing ophthalmologists and can run the gamut in severity. Healing of large corneal wounds, such as alkali burns, involves extended migration of epithelial cells as well as reinnervation of the cornea. Ho ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Human specific STING agonists for the treatment of cancer
SBC: STINGINN, LLC Topic: 102PROJECT SUMMARY Cellular innate immune sensors, such as STING (STIMULATOR OF INTERFERON GENES), have evolved to detect microbial infection of the cell (1-3). STING controls the potent cytosolic DNA-stimulated innate immune pathways and is activated by cyclic dinucleotides (CDNs) such as cyclic di-GMP and cyclic-di-AMP secreted by intracellular bacteria following infection. Alternatively, STING can ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Acute Disseminated Encephalomyelitis (ADEM)
SBC: TRIANGLE THERAPEUTICS INC. Topic: NIAIDPROJECT SUMMARY Acute disseminated encephalomyelitis (ADEM) is an acute autoimmune disease that can present with fever and ataxia as well as loss of consciousness and coma. ADEM largely affects children, is driven by T and B lymphocytes aberrantly activated against a myelin antigen, and is strongly associated with a prior infection or immunization. There is no FDA-approved therapy for the treatmen ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Systemic Lupus Erythematosus
SBC: TRIANGLE THERAPEUTICS INC. Topic: NIAIDPROJECT SUMMARY Lupus is a chronic, systemic autoimmune disease in which cells of the immune system attack organ systems throughout the body including the kidneys, brain, and lungs and that presents heterogeneously with symptoms that can include fever, arthritis, alopecia, stroke, and heart attack. Lupus is driven by autoreactive B and CD4 T cells with a particular role for TfH and TH17 CD4 T cell ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Advanced optics to unlock large field-of-view multiphoton imaging for neuroscience and beyond
SBC: PACIFICOPTICA LLC Topic: 101Project summary Currently available optical components limit biomedical imaging. In particular, in neurobiology, standard microscope components limit the field-of-view and speed of imaging of neuronal activity. Through prior work on BRAIN Initiative project, we have developed approaches for new optical components that expand the field-of-view 5 to 50 times over standard microscopes, with no loss i ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
A digital tool for monitoring speech decline in ALS
SBC: MODALITY.AI , INC Topic: NIDCDPROJECT SUMMARY Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease resulting in the progressive loss of limb, trunk, and head and neck (bulbar) motor function and is the most common adult-onset motor neuron disease. The disease is characterized by significant across-patient heterogeneity in the onset region and in pattern and progression rate, making early and accurate diagno ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Demonstrating miniaturized production of a KOR PET tracer as a proof-of-concept for low-cost distribution of nascent PET neurotracers
SBC: DropletPharm Inc. Topic: NIDAPROJECT SUMMARY / ABSTRACT Positron-emission tomography (PET) studies play a critical role in many areas of neurological health by enabling quantitative in vivo measurements of specific neuroreceptor systems (e.g. receptor density, drug occupancy, endogenous ligand occupancy) to (i) evaluate fundamental hypotheses about disease or (ii) aid in the development of novel treatments targeting those rec ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Endovascular ChemoFilter to Reduce Doxorubicin Toxicity during Intra-Arterial Chemotherapy
SBC: FILTRO MEDICAL INC. Topic: 102PROJECT SUMMARYDosing of chemotherapeutics is limited by systemic toxic side effects. We are developing a new class of image- guided temporarily deployable, endovascular catheter-based medical devices that selectively remove specific drugs from the blood stream to reduce systemic toxicities. The proposed ChemoFilters incorporate specialized materials that bind target drugs in situ through a variet ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
I-RED Southeast XLerator Network
SBC: XLERATEHEALTH, LLC Topic: 500Project Summary I-RED Southeast XLerator Network, powered by XLerateHealth, LLC in collaboration with the University of Kentucky as the lead academic partner institution, proposes to develop a suite of experience-based entrepreneurship education products and commercialization education tools to address the needs of academic institutions and their faculty, researchers, innovators, and graduate/unde ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Extended half-life GlyTR1 combined with checkpoint blockade for Cancer Immunotherapy
SBC: GLYTR THERAPEUTICS, INC. Topic: 102AbstractTreatment of non-resectable recurrent/metastatic solid cancers is currently palliative only and there is an urgent unmet need for novel mechanisms of action and additional paradigm shifting therapeutic options. Antigen- targeting cancer immunotherapies such as bi-specific antibodies (eg Bi-specific T cell engager or BiTE’s) provide a unique approach for cancer immunotherapy. However, app ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health